Robert F. Babczak filed a complaint alleging strict product liability against AbbVie, Inc. in relation to an intraocular medical device called a XEN gel stent used to treat glaucoma. Babczak alleged that, in January and February 2019, he underwent a series of surgeries intended to halt the progression of glaucoma in both eyes. In the final surgery, he was injured by AbbVie’s XEN gel stent that had been placed in his left eye. Months later, Babczak’s surgeon, Dr. Evan Lagouros, informed him by letter that AbbVie had voluntarily recalled the relevant XEN gel stent. Dr. Lagouros’s letter, which was attached to the complaint, stated that a small amount of polishing substance had been found on the sleeves covering the stent’s injector needles. AbbVie did not recommend removing the stent—although conceivable that the polishing agent could get into the eye and irritate it, no patient has complained of this.
Babczak failed to disclose either an independent or a controlled expert witness pursuant to Illinois Supreme Court Rules 213(f)(2), (3) (eff. Jan. 1, 2018) to support his position that a defect in the XEN gel stent, specifically chemical residue, caused his alleged post-surgery injuries of excessive tearing, irritation, and a blind spot. AbbVie, in contrast, had procured the deposition testimony of Babczak’s treating physicians, who opined that Babczak’s injuries were not caused by a chemical residue on the XEN gel stent.
AbbVie moved for summary judgment, arguing that, without an expert, Babczak could not prove the element of causation. Babczak filed a cross-motion for partial summary judgment on the question of liability only, arguing that causation had been established because the XEN gel stent had been subject to a recall and he suffered injuries after the stent had been placed in his eye. The trial court granted summary judgment to AbbVie, agreeing that, without an expert, Babczak could not prove the element of causation. Moreover, the trial court determined that Babczak had not submitted any admissible evidence to contradict AbbVie’s evidence concerning causation. Babczak appealed.
Strict Product Liability
To prevail in a strict product liability action, the plaintiff must prove that: (1) a condition of the product was unreasonably dangerous; (2) the unreasonably dangerous condition existed at the time the product left the manufacturer’s control; and (3) the unreasonably dangerous condition caused the complained-of injury. A plaintiff may establish that a condition of the product was unreasonably dangerous by showing: (1) a manufacturing defect; (2) a design defect; or (3) a failure to warn. When a plaintiff proceeds under a manufacturing defect theory, unreasonable danger is evaluated under the consumer-expectation test. The consumer-expectation test asks whether the product is more dangerous than would be expected by the ordinary consumer with ordinary knowledge common to the community of the product’s characteristics. When a plaintiff proceeds under a design defect theory, unreasonable danger is evaluated under both the consumer-expectation test and the risk-utility test. The risk-utility test asks whether, on balance, the benefits of the design outweigh the risks associated with the design. Finally, when a plaintiff proceeds under a failure to warn theory, unreasonable danger is evaluated by considering whether the manufacturer failed to disclose an unreasonably dangerous condition or instruct on the proper use of the product.
The Appellate Court of Illinois Third District stated in its May 18, 2026 Order: “[I]t is unclear upon which theory of unreasonable danger Babczak proceeds—manufacturing defect, design defect, or failure to warn … Even if we were to assume for the purposes of argument that Babczak produced enough circumstantial evidence from which a trier of fact could find a manufacturing defect, a design defect, or a failure to warn, Babczak failed to produce any admissible evidence from which a trier of fact could reasonably find that a defect caused his alleged injuries of excessive tearing, irritation, and a blind spot … The mere fact that an injury occurred is not a sufficient evidentiary basis from which a trier of fact may infer that a product was defective … Expert testimony is necessary when “more than common knowledge and experience are necessary to understand the issues and to form an opinion.””
“In this case, expert testimony is necessary to understand Babczak’s various theories of causation. Babczak admitted as much when he agreed, at the March 3, 2025, hearing that he would have to dismiss his case if he could not find an expert to support his position. Babczak argues that the polishing agent that was the subject of the recall, or glutaraldehyde used in the standard manufacturing of the product, or some combination of the two, caused his alleged injuries. However, Dr. Lagouros testified that, if a chemical had injured Babczak’s eye, he would have expected to see such an injury within a week of implantation. He did not. Babczak needed to disclose an expert to explain how a polishing agent, yet unnamed, could have caused an extended state of irritation in his eye over the course of years. Similarly, an expert was necessary to explain how the use of glutaraldehyde in the manufacturing process, as opposed to glutaraldehyde in general, could damage the eye. Any number of otherwise dangerous chemicals may be carefully used in manufacturing processes, and, without an expert, Babczak asks this court to engage in speculation that the XEN gel stent implanted into his left eye contained chemical residue that caused his injuries. Because AbbVie has shown that Babczak cannot prove the causation element of his case, the court properly granted summary judgment to AbbVie. Necessarily, the court properly denied Babczak’s motion for partial summary judgment.”
The Illinois appellate court concluded: “In sum, the trial court properly granted summary judgment to AbbVie. AbbVie produced evidence that, if uncontradicted, established that its product did not cause Babczak’s injuries. Rather, AbbVie submitted deposition testimony that explained that the blind spot was a result of the underlying glaucoma condition and the excessive tearing and irritation were more likely the result of a blockage or an intended pressure reduction system called a bleb that, despite its downsides, was nevertheless effective in preventing Babczak from going completely blind. AbbVie successfully shifted the burden of production to Babczak, who failed to disclose an expert to support his position that a chemical residue on the XEN gel stent caused his injuries. As Babczak’s theory of causation was speculative, the trial court also properly denied his motion for partial summary judgment as to liability.”
Source Babczak v. Abbvie Corporation, 2026 IL App (3d) 250414-U.
If you or a loved one suffered serious harm (or worse) as a result of a defective medical device in the United States, you should promptly find a defective medical device lawyer in your state who may investigate your medical device claim for you and represent you or your loved one in a defective medical device case, if appropriate.
Click here to visit our website or call us toll-free in the United States at 800-295-3959 to find medical device attorneys in your U.S. state who may assist you.
Turn to us when you don’t know where to turn.

